X4 Pharmaceuticals Inc Cash Flow Conversion Efficiency
X4 Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has a cash flow conversion efficiency ratio of -0.134x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.79 Million) by net assets ($155.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of X4 Pharmaceuticals Inc (2015–2025)
Cash flow conversion efficiency of X4 Pharmaceuticals Inc from 2015 to 2025. This chart illustrates how X4 Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of X4 Pharmaceuticals Inc for real-time trading data and today's change.
X4 Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
X4 Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
X4 Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see X4 Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JAKKS Pacific Inc
NASDAQ:JAKK
|
0.018x |
|
Interarch Building Products Limited
NSE:INTERARCH
|
0.048x |
|
Bold Eagle Acquisition Corp. Class A Ordinary Shares
NASDAQ:BEAG
|
-0.001x |
|
Aluflexpack AG
SW:AFP
|
0.116x |
|
Shandong Swan Cotton
SHG:603029
|
0.071x |
|
K&F Growth Acquisition Corp. II Unit
NASDAQ:KFIIU
|
0.000x |
|
Polyplex (Thailand) Public Company Limited
BK:PTL-R
|
0.020x |
|
Dadelo S.A.
WAR:DAD
|
0.186x |
Annual Cash Flow Conversion Efficiency for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of X4 Pharmaceuticals Inc from 2015 to 2025. Review financial agility of X4 Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $186.29 Million | $-85.62 Million | -0.460x | +92.22% |
| 2024-12-31 | $22.15 Million | $-130.90 Million | -5.910x | -212.91% |
| 2023-12-31 | $51.10 Million | $-96.51 Million | -1.889x | -81.40% |
| 2022-12-31 | $74.05 Million | $-77.10 Million | -1.041x | +5.41% |
| 2021-12-31 | $64.41 Million | $-70.91 Million | -1.101x | -36.25% |
| 2020-12-31 | $72.80 Million | $-58.82 Million | -0.808x | -117.26% |
| 2019-12-31 | $129.22 Million | $-48.05 Million | -0.372x | +68.40% |
| 2018-12-31 | $21.60 Million | $-25.42 Million | -1.177x | -147.89% |
| 2017-12-31 | $58.71 Million | $-27.87 Million | -0.475x | -136.69% |
| 2016-12-31 | $-16.72 Million | $-21.64 Million | 1.294x | -47.68% |
| 2015-12-31 | $-4.37 Million | $-10.82 Million | 2.473x | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more